AGL Stock Overview
A medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ANGLE plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.12 |
| 52 Week High | UK£0.37 |
| 52 Week Low | UK£0.071 |
| Beta | 0.26 |
| 11 Month Change | 50.00% |
| 3 Month Change | -9.43% |
| 1 Year Change | 23.08% |
| 33 Year Change | -91.11% |
| 5 Year Change | -80.92% |
| Change since IPO | -91.97% |
Recent News & Updates
Recent updates
Will ANGLE (LON:AGL) Spend Its Cash Wisely?
Sep 27
We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate
Mar 20Will ANGLE (LON:AGL) Spend Its Cash Wisely?
Dec 02We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully
Aug 11We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully
Feb 28ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans
Jul 16ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans
Aug 23We're Not Very Worried About ANGLE's (LON:AGL) Cash Burn Rate
May 02What Type Of Shareholders Make Up ANGLE plc's (LON:AGL) Share Registry?
Feb 14
We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate
Dec 22Shareholder Returns
| AGL | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 23.1% | 5.6% | -0.3% |
| 1Y | 23.1% | -1.6% | 6.1% |
Return vs Industry: AGL exceeded the UK Medical Equipment industry which returned -1.6% over the past year.
Return vs Market: AGL exceeded the UK Market which returned 6.1% over the past year.
Price Volatility
| AGL volatility | |
|---|---|
| AGL Average Weekly Movement | 11.3% |
| Medical Equipment Industry Average Movement | 6.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: AGL's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: AGL's weekly volatility has decreased from 23% to 11% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 150 | Andrew David Newland | angleplc.com |
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal transition; and CellKeep Slide, a CTC harvesting technology.
ANGLE plc Fundamentals Summary
| AGL fundamental statistics | |
|---|---|
| Market cap | UK£40.32m |
| Earnings (TTM) | -UK£18.03m |
| Revenue (TTM) | UK£2.02m |
19.1x
P/S Ratio-2.1x
P/E RatioIs AGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGL income statement (TTM) | |
|---|---|
| Revenue | UK£2.02m |
| Cost of Revenue | UK£2.56m |
| Gross Profit | -UK£538.00k |
| Other Expenses | UK£17.49m |
| Earnings | -UK£18.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.056 |
| Gross Margin | -26.58% |
| Net Profit Margin | -890.91% |
| Debt/Equity Ratio | 0% |
How did AGL perform over the long term?
See historical performance and comparison